Hoffmann-la Roche Inc.

F. Hoffmann-la Roche Ag

Siena Biotech S.p.a.

Didier Rombach

Mark Rogers-Evans

Uwe Grether

Matthias Heinrich Nettekoven

Hans Hilpert

Thomas Johannes Woltering

Stephan Roever

Luca Claudio Gobbi

Wolfgang Guba

Bernd Kuhn

Hans G Richter

Katrin Groebke Zbinden

Wolfgang Wostl

Tanja Schulz-Gasch

Benoit Hornsperger

Fabienne Ricklin

Harald Mauser

Atsushi Kimbara

Fionn O'Hara

Joerg Benz

Carsten Kroll

Martin Ritter

Martin Kuratli

Marius Daniel Rinaldo Lutz

Olivier Gavelle

Andrew William Thomas

Jens-Uwe Peters

Wolfgang Haap

Robert Narquizian

Ulrike Obst Sander

Alexander Mayweg

David Banner

Cosimo Dolente

Bjoern Bartels

Roland Humm

Buelent Kocer

Alexander V Mayweg

Matthias Valentin Westphal

Emanuele Gabellieri

Eoin Power

Beat Frei

Charles Bell

Roever Stephan

The invention provides new heterocyclic compounds having the general formula (I) wherein A, L, X, m, n, Rand Rare as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

Heterocyclic compounds as monoacylglycerol lipase inhibitors

The invention relates to a compound of formula (I) wherein Rto Rare defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

Phenyl derivatives as cannabinoid receptor 2 agonists

The invention relates to compound of formula (I) wherein Rto Rare as defined in the description and in the claims. The compound of formula (I) can be used as a medicament.

Pyridine derivatives

The invention relates to a compound of formula (I) wherein A and Rto Rare defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.

The present invention provides a compound of formula (I), having BACE1 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease. 

BACE1 inhibitors

The invention relates to a compound of formula (I) wherein Rto Rare defined as in the description and in the claims. The compound of formula (I) is a CB2 agonist and can be used as an active ingredient in a medicament. 

Pyridine-2-amides useful as CB2 agonists

The present invention relates to 1,4 Thiazepines/Sulfones of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

1,4 thiazepines/sulfones as BACE1 and/or BACE2 inhibitors

The present invention relates to 1,4-Oxazepines of formula I having BACE1 and/or BACE2 inhibitory activity, their manufacture, pharmaceutical compositions containing them and their use as therapeutically active substances. The active compounds of the present invention are useful in the therapeutic and/or prophylactic treatment of e.g. Alzheimer's disease and type 2 diabetes.

1,4-oxazepines as BACE1 and/or BACE2 inhibitors

This invention relates to compounds of the formula wherein A, B and Rto Rare as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE1 and/or BACE2 inhibitors and can be used as medicaments for the therapeutic and/or prophylactic treatment of diseases such as Alzheimer's disease, diabetes, particularly type 2 diabetes, and other metabolic disorders.

2,5,6,7-tetrahydro-[1,4]oxazepin-3-ylamine or 2,3,6,7-tetrahydro-[1,4]oxazepin-5-ylamine compounds

Growing community of inventors

Mulhouse, France

Didier Rombach